Latest Uroplasty (UPI) Headlines
Uroplasty To Participate In The ROTH 26th Annual Conference
PR Newswire - Wed Feb 26, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 26th Annual ROTH Conference on Tuesday, March 11, 2014. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 8:30am PT and meet with investors one on one at the conference at the Ritz Carlton in Laguna Niguel, CA.
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Independence Blue Cross
PR Newswire - Thu Feb 06, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Independence Blue Cross (IBC) has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. IBC covers 2.2 million lives and this decision provides patient coverage for ongoing treatments for up to two years. IBC is the leading health insurer in southeastern Pennsylvania, serving Bucks, Chester, Delaware, Montgomery, and Philadelphia counties.
Can the Rally in Uroplasty (UPI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 8:48AM CST
Can the Rally in Uroplasty (UPI) Shares Continue?
Becton, Dickinson Tops Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 1:48PM CST
International revenues grew 8.9% to $1.17 billion in the quarter, driven by continued strength in emerging markets.
Align Up on Better than Expected Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 11:48AM CST
Align Technology reported its fourth quarter and full year 2013 financial results.
Cardinal Health Tops Earnings Ests, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 2:30PM CST
Cardinal Health's net adjusted earnings slid 1.3% to $313 million from $317 million reported in the second quarter of fiscal 2013.
Uroplasty Appoints Suranjan Roychowdhury, Ph.D. to New Vice President of Research & Development and Clinical Affairs Role
PR Newswire - Mon Jan 27, 3:05PM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it has appointed Dr. Suranjan Roychowdhury as Vice President of Research & Development and Clinical Affairs. This newly created position within the Uroplasty organization was established to provide focus, oversight and guidance to the Company's product pipeline and clinical trials. Dr. Roychowdhury joins Uroplasty with more than 20 years of functional leadership experience and success in the development and commercialization of implantable and disposable medical devices.
Strength Seen in Uroplasty, Inc. (UPI) as Stock Shoots Up 28.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 7:44AM CST
Uroplasty, Inc. was a big mover last session, as the company saw its shares escalate over 28% on the day.
Nasdaq stocks posting largest volume increases
AP - Fri Jan 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Uroplasty (UPI) Hit A Two-Year High Today
at The Street - Fri Jan 24, 2:50PM CST
Uroplasty (UPI) hits a two-year high of $5.40 on Friday after the company reported revenue of $6.4 million, up 14% from the same period one year earlier. Domestic sales of the company's Urgent PC Neuromodulation System grew 19% to $3.2 million, up...
Uroplasty Reports Record Quarterly Revenue
PR Newswire - Thu Jan 23, 3:01PM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported strong financial results for the fiscal 2014 third quarter ended December 31, 2013.
ZTE, JD.com Sign CNY3.5bn Agreement
SinoCast - Fri Jan 17, 4:48AM CST
ZTE Corporation January 16 signed a CNY 3.5 billion strategic cooperation agreement with JD.com, which showed that the two will jointly launch the Youth mobile phones.
Rubenstein Public Relations Appoints New Director Of Communications And Associate Vice President
PR Newswire - Tue Jan 14, 7:32PM CST
Richard Rubenstein, President of Rubenstein Public Relations (RPR), announced today that the agency welcomed two new hires: Roxanne Ducas as Director of Communications and Katalin Bergou as an Associate Vice President. With a breadth of experience in media and public relations, both women bring extensive backgrounds in corporate communications to RPR's team. RPR continues to rise in stature as one of the nation's leading public relations agencies.
Uroplasty To Announce Third Quarter Fiscal 2014 Financial Results On January 23, 2014
PR Newswire - Thu Jan 09, 1:49PM CST
Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the third quarter of fiscal 2014 ended December 31, 2013 at the market close on Thursday, January 23, 2014.
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Medical Mutual
PR Newswire - Mon Dec 23, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Medical Mutual has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Medical Mutual is a large, regional private insurer with approximately 2.7 million covered lives, primarily in Ohio, as well as Georgia, Indiana, Michigan, Pennsylvania, South Carolina and West Virginia.
Uroplasty Names David B. Perry Vice President Of Marketing
PR Newswire - Tue Dec 10, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that David B. Perry has joined the Company as Vice President of Marketing. He joins Uroplasty with nearly 20 years of experience developing, branding and commercializing medical device products resulting in market leadership, share gains and new sales opportunities in global markets.
Uroplasty Provides Update On PTNS Reimbursement
PR Newswire - Wed Dec 04, 5:30AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today provided an update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation (PTNS) procedures delivered via the Company's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.
Uroplasty To Participate In The Piper Jaffray Healthcare Conference
PR Newswire - Thu Nov 21, 5:30AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 3:30pm ET and meet with investors one on one at the conference in New York City.
Global Neuromodulation Market Report 2013 - 2017
M2 - Wed Nov 06, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/nfb62c/neuromodulation) has announced the addition of the "Global Neuromodulation Market Report 2013 - 2017" report to their offering. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder. The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 3.1 Introduction 3.2 Market Segmentation 3.3 Market Dynamics 3.4 Restraints 3.5 Market Share Analysis 4 Global Neuromodulation Market (Internal & External) 5 Geographic Analysis 5.1 Introduction 5.2 North America 5.3 Europe 5.4 Asia 5.5 Rest Of The World 6 Competitive Landscape 6.1 Introduction 6.2 Agreements, Partnerships, Collaborations, Contracts & Joint Ventures 6.3 New Product Launch 6.4 Expansion 6.5 Other Developments 6.6 Approvals 7 Company Profiles Companies Mentioned - Anm Adaptive Neuromodulation Gmbh - Biocontrol Medical, Ltd. - Boston Scientific Corporation - Cerbomed Gmbh - Cyberonics, Inc. - Endostim, Inc. - Enteromedics, Inc. - The Magstim Company Limited - Medtronic, Inc. - Neuronetics, Inc. - Neuropace, Inc. - Neurosigma, Inc. - Nevro Corporation - Rs Medical - Spinal Modulation, Inc. - St. Jude Medical - Synapse Biomedical, Inc. - Uroplasty, Inc. - Zynex, Inc. For more information visit http://www.researchandmarkets.com/research/nf...modulation
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Humana, Inc.
PR Newswire - Tue Oct 29, 6:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Humana, Inc. has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Humana is the sixth largest private insurer in the US with approximately 8.9 million covered lives in 35 states and is also the administrator for Tricare South and several Medicare Advantage plans.
Uroplasty To Participate In The ROTH 26th Annual Conference
PR Newswire - Wed Feb 26, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 26th Annual ROTH Conference on Tuesday, March 11, 2014. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 8:30am PT and meet with investors one on one at the conference at the Ritz Carlton in Laguna Niguel, CA.
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Independence Blue Cross
PR Newswire - Thu Feb 06, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Independence Blue Cross (IBC) has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. IBC covers 2.2 million lives and this decision provides patient coverage for ongoing treatments for up to two years. IBC is the leading health insurer in southeastern Pennsylvania, serving Bucks, Chester, Delaware, Montgomery, and Philadelphia counties.
Can the Rally in Uroplasty (UPI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 8:48AM CST
Can the Rally in Uroplasty (UPI) Shares Continue?
Becton, Dickinson Tops Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 1:48PM CST
International revenues grew 8.9% to $1.17 billion in the quarter, driven by continued strength in emerging markets.
Align Up on Better than Expected Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 11:48AM CST
Align Technology reported its fourth quarter and full year 2013 financial results.
Cardinal Health Tops Earnings Ests, Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 2:30PM CST
Cardinal Health's net adjusted earnings slid 1.3% to $313 million from $317 million reported in the second quarter of fiscal 2013.
Uroplasty Appoints Suranjan Roychowdhury, Ph.D. to New Vice President of Research & Development and Clinical Affairs Role
PR Newswire - Mon Jan 27, 3:05PM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it has appointed Dr. Suranjan Roychowdhury as Vice President of Research & Development and Clinical Affairs. This newly created position within the Uroplasty organization was established to provide focus, oversight and guidance to the Company's product pipeline and clinical trials. Dr. Roychowdhury joins Uroplasty with more than 20 years of functional leadership experience and success in the development and commercialization of implantable and disposable medical devices.
Strength Seen in Uroplasty, Inc. (UPI) as Stock Shoots Up 28.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 7:44AM CST
Uroplasty, Inc. was a big mover last session, as the company saw its shares escalate over 28% on the day.
Nasdaq stocks posting largest volume increases
AP - Fri Jan 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Uroplasty (UPI) Hit A Two-Year High Today
at The Street - Fri Jan 24, 2:50PM CST
Uroplasty (UPI) hits a two-year high of $5.40 on Friday after the company reported revenue of $6.4 million, up 14% from the same period one year earlier. Domestic sales of the company's Urgent PC Neuromodulation System grew 19% to $3.2 million, up...
Uroplasty Reports Record Quarterly Revenue
PR Newswire - Thu Jan 23, 3:01PM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported strong financial results for the fiscal 2014 third quarter ended December 31, 2013.
ZTE, JD.com Sign CNY3.5bn Agreement
SinoCast - Fri Jan 17, 4:48AM CST
ZTE Corporation January 16 signed a CNY 3.5 billion strategic cooperation agreement with JD.com, which showed that the two will jointly launch the Youth mobile phones.
Rubenstein Public Relations Appoints New Director Of Communications And Associate Vice President
PR Newswire - Tue Jan 14, 7:32PM CST
Richard Rubenstein, President of Rubenstein Public Relations (RPR), announced today that the agency welcomed two new hires: Roxanne Ducas as Director of Communications and Katalin Bergou as an Associate Vice President. With a breadth of experience in media and public relations, both women bring extensive backgrounds in corporate communications to RPR's team. RPR continues to rise in stature as one of the nation's leading public relations agencies.
Uroplasty To Announce Third Quarter Fiscal 2014 Financial Results On January 23, 2014
PR Newswire - Thu Jan 09, 1:49PM CST
Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the third quarter of fiscal 2014 ended December 31, 2013 at the market close on Thursday, January 23, 2014.
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Medical Mutual
PR Newswire - Mon Dec 23, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Medical Mutual has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Medical Mutual is a large, regional private insurer with approximately 2.7 million covered lives, primarily in Ohio, as well as Georgia, Indiana, Michigan, Pennsylvania, South Carolina and West Virginia.
Uroplasty Names David B. Perry Vice President Of Marketing
PR Newswire - Tue Dec 10, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that David B. Perry has joined the Company as Vice President of Marketing. He joins Uroplasty with nearly 20 years of experience developing, branding and commercializing medical device products resulting in market leadership, share gains and new sales opportunities in global markets.
Uroplasty Provides Update On PTNS Reimbursement
PR Newswire - Wed Dec 04, 5:30AM CST
Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today provided an update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation (PTNS) procedures delivered via the Company's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.
Uroplasty To Participate In The Piper Jaffray Healthcare Conference
PR Newswire - Thu Nov 21, 5:30AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 3:30pm ET and meet with investors one on one at the conference in New York City.
Global Neuromodulation Market Report 2013 - 2017
M2 - Wed Nov 06, 4:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/nfb62c/neuromodulation) has announced the addition of the "Global Neuromodulation Market Report 2013 - 2017" report to their offering. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS). The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder. The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 3.1 Introduction 3.2 Market Segmentation 3.3 Market Dynamics 3.4 Restraints 3.5 Market Share Analysis 4 Global Neuromodulation Market (Internal & External) 5 Geographic Analysis 5.1 Introduction 5.2 North America 5.3 Europe 5.4 Asia 5.5 Rest Of The World 6 Competitive Landscape 6.1 Introduction 6.2 Agreements, Partnerships, Collaborations, Contracts & Joint Ventures 6.3 New Product Launch 6.4 Expansion 6.5 Other Developments 6.6 Approvals 7 Company Profiles Companies Mentioned - Anm Adaptive Neuromodulation Gmbh - Biocontrol Medical, Ltd. - Boston Scientific Corporation - Cerbomed Gmbh - Cyberonics, Inc. - Endostim, Inc. - Enteromedics, Inc. - The Magstim Company Limited - Medtronic, Inc. - Neuronetics, Inc. - Neuropace, Inc. - Neurosigma, Inc. - Nevro Corporation - Rs Medical - Spinal Modulation, Inc. - St. Jude Medical - Synapse Biomedical, Inc. - Uroplasty, Inc. - Zynex, Inc. For more information visit http://www.researchandmarkets.com/research/nf...modulation
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Humana, Inc.
PR Newswire - Tue Oct 29, 6:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Humana, Inc. has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Humana is the sixth largest private insurer in the US with approximately 8.9 million covered lives in 35 states and is also the administrator for Tricare South and several Medicare Advantage plans.
